Reirradiation and teclistamab in relapsed multiple myeloma: initial experience in two heavily pretreated patients with extensive disease
Carsten Nieder, Siri U Hansen, Terje S Solhaug, Randi F Hallstensen · 2026
Read Reirradiation and teclistamab in relapsed multiple myeloma: initial experience in two heavily pretreated patients with extensive disease by Carsten Nieder, Siri U Hansen, Terje S Solhaug, Randi F Hallstensen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13551319.txt.
Description
Carsten Nieder's team reports on two heavily treated patients whose widespread multiple myeloma was treated with the immune drug teclistamab plus radiotherapy, in a 2026 case report from one centre. One patient had spread to the liver and the other to the membranes around the brain. Both had already had several rounds of drug therapy and radiation to many sites. Their past care left a large total dose to the bone marrow.
Both patients soon had severe blood-cell harm, with very low white cells and platelets, but got better within a few weeks. Radiation caused no other acute harm above a mild grade. The authors warn that such combined care in complex cases may need hospital stay and close watch by a skilled blood-cancer team. That team may also need to handle immune reactions and dangerous infections tied to low white-cell counts.
Catalog record
| CREATOR | Carsten Nieder, Siri U Hansen, Terje S Solhaug, Randi F Hallstensen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |